REC Ref	IRAS No	Name of Trial	First Patient Recruited?	Date of First Patient Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Patient Recruited	Duration between Date Site Selected and First Patient Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
14/WA/1118	159836	A Phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV)-positive oropharyngeal cancer	No					29/07/2015	10/01/2018						D - Sponsor Delays	Sponsor
17/WS/0030	191416	A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	Yes	17/07/2017	10	45	55	05/01/2017	23/05/2017	12/04/2017	18/05/2017	02/06/2017		07/06/2017		
17/EE/0097	186866	A Phase I Open-Labelled Trial investigating immunisation strategies using Ad4, MVA and rpg140 combinations in order to maximise antibody responses	Yes	09/03/2018	6	177	183	16/01/2017	07/09/2017	07/09/2017	16/01/2017	13/09/2017		06/10/2017	D - Sponsor Delays	Sponsor
16/EE/0065	192416	Survival Improvement with Colecalciferol in Patients on Dialysis The SIMPLIFIED Registry Trial	No		140			26/06/2016	17/11/2017	29/07/2016	26/06/2016	06/04/2018			D - Sponsor Delays	Sponsor
															H - Contracting delays	
17/LO/0524	202816	Catheter ABlation of LOw VOltage regions in the treatment of persistent Atrial Fibrillation (ABLOVO-AF study)	Yes	24/08/2017	18	80	98	07/03/2017	18/05/2017	18/05/2017	07/03/2017	05/06/2017		05/06/2017	B - Suspended by sponsor	Sponsor
17/EE/0330	213102	A Prospective, Non-randomized, Consecutive Series, Multicentre, Observational Study to Evaluate the Clinical Outcome of Ceramic-on-Ceramic Hip Resurfacing Arthroplasty Using the H1 hip joint ceramic non-porous non-cemented prosthesis	Yes	26/09/2017	8	1	9	17/09/2017	17/09/2017	22/09/2017	25/09/2017	25/09/2017		25/09/2017		
17/LO/0797	220423	A multi-center, non-randomized study to evaluate the safety and effectiveness of the Abre venous self-expanding stent system in patients with symptomatic iliofemoral venous outflow obstruction.	No					28/11/2016	27/04/2017	01/08/2017	17/01/2018				B - Suspended by sponsor	Sponsor
17/SC/0411	217829	A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VGX-3100X (DNA PLASMID VECTORS EXPRESSING HPV-16 E6/E7, HPV-18 E6/E7) DELIVERED intramuscularly FOLLOWED BY EP WITH CELLECTRA® 5PSP FOR THE TREATMENT OF HISTOLOGICALLY PROVEN CIN2 OR CIN3 ASSOCIATED WITH HPV-16 AND/OR HPV-18	No					01/06/2016	23/08/2017						A - Permissions delayed/denied	Neither
															D - Sponsor Delays	
16/NE/0415	217915	A Phase 2a, Open-Label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335 and Odalasvir (ODV), with or without Simeprevir (SMV), in Treatment-Naïve Subjects with Genotype 1, 2 or 3 Chronic Hepatitis C infection with or without compensated Child Pugh A Cirrhosis	No		35			16/12/2016	01/06/2017	28/02/2017	16/12/2016	06/07/2017	Sponsor declined site con		B - Suspended by sponsor	Sponsor
17/LO/0465	218759	ADJUNCTIVE GP ABLATION IN REDO-PVI STUDY (ADD-GP): PAROXYSMAL ATRIAL ARRHYTHMIAS AFTER PULMONARY VEIN ISOLATION ARE DRIVEN BY ECTOPY-TRIGGERING LEFT ATRIAL GANGLIONATED PLEXI	Yes	21/07/2017	54	37	91	24/02/2017	21/04/2017	21/04/2017	07/06/2017	14/06/2017		02/06/2017	A - Permissions delayed/denied	NHS Provid
															F - No patients seen	
16/LO/1979	193891	A randomised trial of non-Selective versus selective adjuvant Therapy in high risk Apparent sTage 1 Endometrial Cancer	Yes	19/03/2018	9	192	201	04/01/2017	30/08/2017	20/12/2016	06/09/2017	08/09/2017		08/09/2017	G - No patients consented	Neither
17/LO/0705	214843	TRIAL ON RADICAL UPFRONT SURGERY IN ADVANCED OVARIAN CANCER AMENDMENT FOR GERMANY WITH EXTENDED PART FOR FRAGILITY AND LONG TERM QUALITY OF LIFE	Yes	04/09/2017	60	34	94	02/06/2017	02/06/2017	28/07/2017	27/07/2017	01/08/2017		03/08/2017	G - No patients consented	Sponsor
															H - Contracting delays	
16/EM/0436	213166	SINGLE ARM, STUDY OF ALXN1210 IN COMPLEMENT INHIBITOR TREATMENT-NAIVE ADULT AND ADOLESCENT PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS)	No		23			16/08/2017	16/08/2017	07/12/2016	16/08/2017	08/09/2017		15/09/2017	I - Rare diseases	Neither

17/LO/1991	172966	A comparative study of two popular weight-loss diets and their effect on the metabolic profiles of: i) Healthy overweight and obese individuals ii) Overweight and obese breast cancer follow-up patients	No		42				08/11/2017	18/12/2017		20/12/2017			D - Sponsor Delays	Sponsor
16/WS/0197	186191	An adaptive multi-arm phase II trial of maintenance targeted therapy after chemotherapy in metastatic urothelial cancer	No		129			01/02/2017	30/05/2017	01/02/2017	02/08/2017	06/10/2017		12/10/2017	D - Sponsor Delays	Sponsor
															H - Contracting delays	
17/EE/0080	220727	A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen	Yes	23/10/2017	29	96	125	30/03/2017	20/06/2017	09/06/2017	08/05/2017	19/07/2017		04/08/2017	I - Rare diseases	Neither
17/EE/0079	220827	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Treated Concomitantly with Rituximab or Cyclophosphamide/Azathioprine	Yes	23/01/2018	92	0	92	20/02/2017	23/10/2017	06/04/2017	20/02/2017	23/01/2018		23/01/2018	D - Sponsor Delays	Sponsor
16/NS/0094	206213	BioImpedance Spectroscopy to Maintain Renal Output: The BISTRO Trial	Yes	10/11/2017	65	30	95	23/02/2017	07/08/2017	04/10/2016	23/02/2017	11/10/2017		12/10/2017	D - Sponsor Delays	Sponsor
17/EE/0081	219405	An open label, single arm pilot study of OncoSil™, administered to study participants with unresectable locally advanced pancreatic adenocarcinoma, given in combination with FOLFIRINOX or gemcitabine+nab-paclitaxel chemotherapies.	Yes	13/10/2017	62	99	161	26/02/2017	05/05/2017	08/05/2017	29/06/2017	06/07/2017		06/07/2017	A - Permissions delayed/denied	Neither
															I - Rare diseases	
17/WM/0124	219181	Assessment of arterial stiffness in patients with end-stage kidney disease using shear-wave elastography	Yes	15/06/2017	42	2	44	04/04/2016	02/05/2017	18/04/2017	04/04/2017	13/06/2017		13/06/2017		
17/LO/0566	218514	An experimental medicine study to validate The 18 kD Translocator Protein as a novel neuroimmunodulatory target	No		25			17/03/2017	11/01/2018	19/12/2017	17/03/2017	05/02/2018			G - No patients consented	Neither
17/SC/0130	33635	A Phase Ib Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 in Combination with Exemestane or Fulvestrant Followed by a Parallel Randomized Phase II Study Comparing the Combination of GS-5829 with Exemestane to Exemestane Alone and the Combination of GS-5829 with Fulvestrant to Fulvestrant Alone in Subjects with Advanced Estrogen Receptor Positive Breast Cancer	No						03/04/2017				Site declined to participate			
17/NW/0175	222859	A Phase 1b Open-Label, Dose Escalation Study of PRTX-100 in Adult patients with Persistent/Chronic Immune Thrombocytopenia	Yes	28/06/2017	58	6	64	20/10/2016	25/04/2017	19/05/2017	16/06/2017	22/06/2017		23/06/2017		
16/EM/0465	214926	A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations	No		285			14/03/2017	20/04/2017	19/01/2017	29/06/2017	30/01/2018			D - Sponsor Delays	Sponsor
															H - Contracting delays	
17/NW/0180	220257	A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy.	No		108			15/03/2017	24/04/2017	04/04/2017	02/08/2017	10/08/2017		14/08/2017	D - Sponsor Delays	Sponsor
17/LO/0746	218349	In comparison to usual care alone, does an adjunctive pre-surgery dietetic service improve the post-surgical nutritional outcomes for patients with pancreatic cancer? A pilot study	No		1			20/02/2017	08/08/2017	01/08/2017	08/08/2017	09/08/2017		09/08/2017	B - Suspended by sponsor	Neither
															F - No patients seen	
															G - No patients consented	
17/EM/0116	222773	A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients with Parkinson's Disease Experiencing End of Dose "Wearing-Off"	Yes	18/07/2017	0	47	47	27/03/2017	01/06/2017	22/03/2017	27/03/2016	01/06/2017		11/07/2017	D - Sponsor Delays	Sponsor

17/LO/0862	195365	The effects of fruits and vegetables on vascular function in prehypertensive participants: a pilot study	Yes	13/09/2017	2	53	55	21/04/2017	20/07/2017	04/07/2017	21/04/2017	22/07/2017		04/09/2017		
17/NE/0036	208636	A prospective, multicentre, randomised, controlled study evaluating SIR-Spheres Y-90 resin microspheres preceding standard cisplatin-gemcitabine (CIS-GEM) chemotherapy versus CIS-GEM chemotherapy alone as first-line treatment of patients with unresectable intrahepatic cholangiocarcinoma (SIRCCA)	Yes	08/01/2018	245	35	280	03/04/2017	03/04/2017	30/05/2017	30/11/2017	04/12/2017		07/12/2017	D - Sponsor Delays	Sponsor
															F - No patients seen	
															H - Contracting delays	
															I - Rare diseases	
17/LO/0783	225826	A Multicenter, Parallel-Group, Randomized, Cross-Over Trial to Compare the Efficacy of LUMINITY® and SonoVue® in the Evaluation of Left Ventricular Endocardial Border Definition	No		40			06/04/2017	24/08/2017	24/08/2017	25/09/2017	03/10/2017		16/01/2018	J - Other	NHS Provid
17/WS/0120	225090	A multi-center, double-blind, placebo-controlled, Phase 4 study in patients with pulmonary arterial hypertension to assess the effect of selexipag on daily life physical activity and patient's self-reported symptoms and their impacts	Yes	11/01/2018	183	27	210	04/05/2017	15/06/2017	24/07/2017	13/12/2017	15/12/2017		21/12/2017	E - Staff availability issues	Sponsor
															H - Contracting delays	
															I - Rare diseases	
17/SC/0291	226509	The DEFINE PCI study: Physiologic assessment of coronary stenosis following PCI.	Yes	13/02/2018	139	63	202	09/03/2017	26/07/2017	29/08/2017	04/12/2017	12/12/2017		21/12/2017	E - Staff availability issues	Sponsor
															J - Other	
17/EM/0241	223736	Safety and efficacy analysis of FRED/FRED Jr embolic device in aneurysm treatment	Yes	23/11/2017	62	65	127	05/07/2017	19/07/2017	08/08/2017	18/09/2017	19/09/2017		19/09/2017	F - No patients seen	NHS Provid
															H - Contracting delays	
16/EE/0463	214371	An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease.	Yes	20/10/2017	71	28	99	12/06/2017	13/07/2017	30/01/2017	18/09/2017	22/09/2017		04/10/2017	A - Permissions delayed/denied	Both
															H - Contracting delays	
17/SC/0253	226685	A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adju-vant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer.	No		187			30/05/2017	31/05/2017	05/07/2017	30/11/2017	04/12/2017		03/01/2018	D - Sponsor Delays	Sponsor
															G - No patients consented	
17/LO/1169	224716	Efficacy and usability of Ostom-i device in patients with ileostomy. A pilot study	No		1			25/09/2017	22/11/2017	20/10/2017		23/11/2017		23/11/2017	G - No patients consented	Neither
17/NW/0254	225698	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy	Yes	27/11/2017	85	46	131	05/05/2017	19/07/2017	17/07/2017	25/09/2017	12/10/2017		25/10/2017	A - Permissions delayed/denied	Sponsor
															D - Sponsor Delays	
															F - No patients seen	
															H - Contracting delays	
17/NE/0149	224550	(M16-298) randomized, double-blind, placebo-controlled phase 3 study of rovalpituzumab tesirine (Rova-T) as maintenance therapy following four cycles of firstline therapy with a platinum doublet in subjects with extensive stage disease (ED) SCLC	No		142			10/05/2017	20/06/2017	19/06/2017	06/09/2017	09/11/2017		21/11/2017	A - Permissions delayed/denied	Both
															H - Contracting delays	
17/LO/0939	219566	Patient Empowerment Through Predictive Personalised Decision Support (PEPPER)	Yes	09/01/2018	35	22	57	12/09/2017	13/11/2017	08/11/2017	12/09/2017	18/12/2017		18/12/2017		

16/WM/0448	212745	A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients with Cytomegalovirus (CMV) Infections that are Refractory or Resistant to Treatment with Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir.	No		222			05/04/2017	05/04/2017	08/02/2017	23/10/2017	13/11/2017		16/11/2017	D - Sponsor Delays	Sponsor
17/ES/0051	223060	CANC 33870: A Phase II Open-Label Study of NUC-1031 in Patients with Platinum-Resistant Ovarian Cancer	Yes	19/01/2018	131	66	197	07/06/2017	06/07/2017	05/07/2017		14/11/2017		17/11/2017	D - Sponsor Delays	Sponsor
															H - Contracting delays	
17/LO/1095	225278	Investigation of the metabolic effects of duodenal resurfacing on insulin resistant women wIth polycystic ovarian syndrome	No		39			09/06/2017	09/02/2018	04/09/2017	09/06/2017	20/03/2018		21/03/2018		
17/EE/0264	228153	A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non-Small-Cell Lung Cancer (NSCLC) (POSEIDON)	No		75			02/06/2017	13/09/2017	12/09/2017	20/11/2017	27/11/2017		27/11/2017	D - Sponsor Delays	Sponsor
															F - No patients seen	
															H - Contracting delays	
17/EE/0177	220722	A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) versus Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM).	Yes	03/10/2017	63	7	70	31/05/2017	25/07/2017	24/07/2017	18/09/2017	26/09/2017		27/09/2017		
17/SC/0554	225522	A Phase III, multicenter, randomized controlled study to compare safety and efficacy of a haploidentical HSCT and adjunctive treatment with ATIR101, a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells, versus a haploidentical HSCT with post-transplant cyclophosphamide in patients with a hematologic malignancy (HATCY study).	No		188			31/05/2017	10/10/2017	23/02/2018	21/03/2018	16/04/2018			D - Sponsor Delays	Sponsor
															H - Contracting delays	
															J - Other	
16/WA/0156	204506	Minimally invasive thoracoscopically-guided right minithoracotomy versus conventional sternotomy for mitral valve repair: a multicentre randomised controlled trial (UK Mini Mitral).	Yes	13/03/2018	205	26	231	14/06/2017	25/07/2017	19/06/2016	31/01/2018	15/02/2018		15/02/2018	A - Permissions delayed/denied	Sponsor
															D - Sponsor Delays	
															E - Staff availability issues	
															H - Contracting delays	
17/LO/1590	229278	A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) plus Chemotherapy (XP or FP) versus Placebo plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects with Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585).	No		121			11/07/2017	01/11/2017	27/10/2017		02/03/2018		02/03/2018	A - Permissions delayed/denied	Sponsor
															D - Sponsor Delays	
															H - Contracting delays	
17/SW/0127	225959	A multicentre randomised trial of First Line treatment pathways for newly diagnosed Immune Thrombocytopenia: Standard steroid treatment versus combined steroid and mycophenolate.	No		205			19/06/2017	19/06/2017	03/07/2017	09/01/2018	10/01/2018			J - Other	NHS Provid
17/LO/1441	219916	SYNCope EDUcation for patients during tilt-table tests	Yes	20/03/2018	26	36	62	02/08/2017	17/01/2018	12/09/2017		12/02/2018				
17/NE/0174	224141	A PERFORMANCE EVALUATION STUDY OF ARQUER'S MCM5 ELISA TEST TO AID IN THE MONITORING OF BLADDER CANCER RECURRENCE	Yes	06/09/2017	65	5	70	27/06/2017	28/06/2017	13/06/2017	08/08/2017	01/09/2017		01/09/2017		
17/LO/1457	2277777	Randomised controlled trial of mechanochemical ablation versus cyanoacrylate adhesive for the treatment of varicose veins	Yes	06/11/2017	9	5	14	01/08/2017	23/10/2017	19/09/2017	30/10/2017	01/11/2017		30/10/2017		
17/LO/1447	226100	The effectiveness of a focused point-of-care duplex ultrasound scan as a bedside screening tool to detect peripheral arterial disease in diabetes.	No		60			30/08/2017	06/11/2017	21/12/2017	15/12/2017	05/01/2018			A - Permissions delayed/denied	Neither

17/WS/0192	216416	Randomised controlled trial of foam sclerotherapy versus ambulatory phlebectomy for the treatment of varicose vein tributaries	Yes	22/01/2018	38	61	99	21/08/2017	15/10/2017	15/10/2017		22/11/2017			E - Staff availability issues	Neither
															F - No patients seen	
															G - No patients consented	
															J - Other	
14/LO/0801	137312	Improving radical treatment through MRI evaluation of pelvic sigmoid cancers	No		225			08/08/2017	08/08/2017	15/06/2016	21/03/2018	21/03/2018		27/03/2018	D - Sponsor Delays	Sponsor
															H - Contracting delays	
17/LO/1247	228533	RANDOMIZED, OPEN LABEL, MULTICENTRE, PHASE 3 STUDY OF ROVALPITUZUMAB TESIRINE COMPARED WITH TOPOTECAN FOR SUBJECTS WITH ADVANCED OR METASTIC DLL3 SMALL CELL LUNG CANCER (SCLC) WHO HAVE FIRST DISEASE PROGRESSION DURING OR FOLLOWING FRONT LINE PLATINUM -BASED CHEMOTHERAPY	No		164			30/01/2017	22/08/2017	15/08/2017		02/02/2018		06/02/2018	A - Permissions delayed/denied	NHS Provid
															H - Contracting delays	
17/LO/1040	226283	p53 Suppressor Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Phase II Study of Systemic Pegylated Liposomal Doxorubicin Chemotherapy With APR-246	Yes	17/11/2017	1	31	32		16/10/2017	04/09/2017		17/10/2017		27/10/2017		
17/YH/0311	229294	A Modular, Multipart, Multiarm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination with Anti-cancer Treatments in Patients with Advanced Malignancies	Yes	28/11/2017	79	4	83	29/08/2017	06/09/2017	30/10/2017		24/11/2017		24/11/2017	D - Sponsor Delays	Both
															H - Contracting delays	
14/LO/0843	136843	The role of MRI in improving surgical technique and outcomes in exenterative pelvic surgery for locally extensive primary or recurrent rectal cancer	No		201			01/09/2017	01/09/2017	18/01/2017	21/03/2018	21/03/2018		27/03/2018	D - Sponsor Delays	Sponsor
															H - Contracting delays	
17/WS/0180	225790	A Phase 111b, Randomised, Double-blind, Placebocontrolled, MulticentreStudy of Olaparib Maintenance Retreatment in Patients with EpithelialOvarian Cancer Previously Treated With a PARPi and Responding toRepeat Platinum Chemotherapy (OReO)	No		174			11/09/2017	13/10/2017	02/02/2018		05/04/2018		29/03/2018	H - Contracting delays	Sponsor
17/EE/0340	213113	INTERIM: a randomised phase II feasibility study of INTERmittent versus continuous dosing of oral targeted combination therapy (BRAF+ MEKi) in patients with BRAFV600 mutant stage 3 unresectable or metastatic Melanoma.	No		82			01/08/2017	25/10/2017	15/10/2017	03/01/2018	15/01/2018		27/02/2018	A - Permissions delayed/denied	NHS Provid
17/SC/0394	229032	An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated with Ruxolitinib.	Yes	19/12/2017	101	26	127	07/08/2017	14/08/2017	23/10/2017		23/11/2017		12/12/2017	D - Sponsor Delays	Sponsor
17/LO/1149	220763	A Phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled study to assess the efficacy and safety of maribavir compared to valganciclovir for the treatment of cytomegalovirus (CMV) infection in hematopoietic stem cell transplant recipients.	No		194			26/07/2017	26/07/2017	12/09/2017	09/10/2017	05/02/2018		06/03/2018	D - Sponsor Delays	Sponsor
17/EM/0338	229242	A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors	No					04/09/2017	07/02/2018	24/01/2018					D - Sponsor Delays	Sponsor
17/LO/1320	229845	Single-arm, phase II study of Luspatercept (ACE-536) in anemic patients with MPN-associated myelofibrosis.	No		153			10/08/2017	10/08/2017	27/10/2017	22/12/2017	10/01/2018		19/02/2018	A - Permissions delayed/denied	Sponsor
															D - Sponsor Delays	
															H - Contracting delays	
17/SC/0408	228262	A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination with Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease.	No		200			18/09/2017	18/09/2017	19/09/2017	06/04/2018	06/04/2018			D - Sponsor Delays	Sponsor

17/LO/1429	223671	A Two-Part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL).	No		191			06/09/2017	06/09/2017	29/01/2018	12/01/2018	16/03/2018		21/03/2018	D - Sponsor Delays	Sponsor
															J - Other	
17/LO/1847	216867	A randomised phase II trial of Selinexor, cyclophosphamide and prednisone vs cyclophosphamide and prednisone in relapsed or refractory multiple myeloma (RRMM) patients.	No					22/11/2017	14/02/2018	04/01/2018					D - Sponsor Delays	Sponsor
17/LO/1500	224823	A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-controlled Study of AG-120 in Combination with Azacitidine in Subjects = 18 Years of Age with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation Who are candidates for Non-intensive Therapy.	No					05/02/2018	13/02/2018						D - Sponsor Delays	Sponsor
17/SC/0201		Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study.	No					29/01/2018	22/03/2018	18/10/2017						
17/EM/0371	229496	Strategic Management to Optimize Response To Cardiac Resynchronization Therapy	No					10/07/2017	26/03/2018	21/11/2017						
17/LO/1695	234684	A Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Medicated Gene Transfer of Human Factor VIII in Haemphilia A Patients with Residual FVIII Levels 1 IU/dl Receiving Prophylactic FVIII Infusions.	No		65			09/10/2017	09/10/2017	24/11/2017		13/12/2017			A - Permissions delayed/denied	Neither
16/EM/0382	210424	A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction.	No		40			12/10/2017	23/02/2018	05/12/2016	08/02/2018	04/04/2018				
17/LO/1918	229435	Does Neuromuscular Electrical Stimulation Improve the Absolute Walking Distance in Patients with Intermittent Claudication (NESIC) compared to best available treatment? A Multicentre Randomised Controlled Study	Yes	08/03/2018	45	20	65	09/11/2017	02/01/2018	29/01/2018		16/02/2018		16/02/2018	E - Staff availability issues	
17/LO/1592	225931	AN OPEN-LABEL, MULTICENTER EXTENSION STUDY IN PATIENTS PREVIOUSLY ENROLLED IN A GENENTECHâˆ’ AND/OR F. HOFFMANN-LA ROCHE LTDâˆ’SPONSORED ATEZOLIZUMAB STUDY	No		89			15/09/2017	20/09/2017	07/11/2017	12/12/2017	18/12/2017		19/12/2017	A - Permissions delayed/denied	Neither
17/NE/0151	223815	Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia (SGI-110-06).	No		135			01/11/2017	01/11/2017	19/07/2017	07/03/2018	16/03/2018		06/04/2018	D - Sponsor Delays	Sponsor
17/LO/1929	233885	A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Epacadostat, Pembrolizumab, and the EXTREME Regimen as First line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)	No		148			02/11/2017	13/11/2017	05/02/2018	27/03/2018	10/04/2018			H - Contracting delays	NHS Provid
17/EE/0481	226412	Pre-Implantation trial of Histopathology In renal Allografts	No		74			08/11/2017	24/11/2017	05/01/2018	08/11/2017	06/02/2018			A - Permissions delayed/denied	Neither
18/LO/0196	237129	A Study of Flat and Circadian Insulin Infusion Rates in Continuous Subcutaneous Insulin Infusion (CSII) in Adults with Type 1	No		16			10/01/2018	27/02/2018			15/03/2018				
17/LO/0118	220143	Maternal Moments: Investigating music listening of well-being in pregnancy	No		7			03/11/2017	14/12/2017	28/04/2017	14/12/2017	21/12/2017			G - No patients consented	Neither
17/NW/0351	224954	A phase II single arm clinical trial of a Tailored ImmunoTherapy Approach with Nivolumab in subjects with metastatic or advanced Renal Cell Carcinoma	No						12/09/2017						A - Permissions delayed/denied	NHS Provid
17/EE/0368	213669	STRESS-L: STudy into the REversal of Septic Shock with Landiolol (Beta Blockade)	No					12/10/2017	28/03/2018	10/11/2017						
17/EE/0480	235288	A Phase 3 Randomized, Double-Blind Trial of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB024360) or Placebo in Participants with Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)	No		117			27/11/2017	14/12/2017	05/02/2018	27/03/2018	10/04/2018			D - Sponsor Delays	Sponsor

														H - Contracting delays	
17/LO/2059	235808	A Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients who have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease (KEYNOTE-698/ECHO-303)	No		103			27/11/2017	14/12/2017	29/01/2018	20/03/2018	27/03/2018			D - Sponsor Delays	Sponsor
														H - Contracting delays	
17/SC/0641	238111	A Phase 1/2 Safety, Tolerability, and Efficacy Study of BMN 270, an Adeno-Associated Virus Vector–Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients with Residual FVIII Levels = 1 IU/dL and Pre-existing Antibodies Against AAV5	No					08/12/2017	08/12/2017				Sponsor declined site confirmation			
18/WM/0022	237623	AG-348 in Regularly Transfused Adult Subjects with PK Deficiency	No					22/10/2017	19/01/2018						D - Sponsor Delays	Sponsor
18/LO/0054	236047	Microneedle sensing of beta-lactam antibiotic concentrations in human interstitial fluid	No		14			06/07/2017	21/03/2018	14/02/2018	06/07/2017	04/04/2018				
17/LO/0103	216784	A Multicenter, Double-Blind, Double-Dummy Study to Explore the Long-Term Safety of TEV-48125 for the Prevention of Cluster Headache	No		15			20/06/2017	20/12/2017	05/07/2017		04/01/2018			G - No patients consented	Neither
17/LO/0089	219229	A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir for 12 Weeks in Subjects with Chronic HCV Infection Who are on Dialysis for End Stage Renal Disease	Yes	15/07/2017	21	29	50	27/01/2017	26/05/2017	27/03/2017	27/01/2017	16/06/2017		16/06/2017		
17/LO/0102	215259	A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/ Subcutaneous and Subcutaneous) of TEV-48125 versus Placebo for the Prevention of CHRONIC Cluster Headaches (CCH)	No		11			12/12/2016	22/12/2017	14/07/2017	12/12/2016	02/01/2018			D - Sponsor Delays	Sponsor
16/EE/0421	209972	A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients with Open-Angle Glaucoma or Ocular Hypertension	No					15/02/2017	25/04/2017	13/01/2017					D - Sponsor Delays	Sponsor
															H - Contracting delays	
17/LO/0444	218822	A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-ActingAntiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection	Yes	19/06/2017	1	10	11	08/03/2017	08/06/2017	05/05/2017	08/03/2017	09/06/2017		09/06/2017		
17/LO/0742	219709	A randomised controlled comparison of effectiveness of facemask pre-oxygenation and Transanal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) in bariatric patients undergoing general anesthesia	No		3			15/02/2017	10/07/2017	29/06/2017	13/07/2017	13/07/2017		17/07/2017	D - Sponsor Delays	Sponsor
16/WM/0285	202235	A Double Blind, Randomized, Placebo Controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy on LDL-C of Evolocumab (AMG 145) in Subjects with HIV and with Hyperlipidemia and/or Mixed Dyslipidemia	Yes	01/08/2017	16	12	28	17/03/2017	04/07/2017	22/06/2017	17/03/2017	20/07/2017		05/07/2017		
17/LO/0401	217921	An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination with Sofosbuvir and Ribavirin in Chronic Hepatitis C (HCV) Infected Subjects Who Have Experienced Virologic Failure in AbbVie HCV Clinical Studies.	Yes	06/06/2017	22	13	35	02/05/2017	02/05/2017	23/03/2017	21/03/2017	24/05/2017		31/05/2017		
17/LO/0096	220205	A Phase 3b, 12-month, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of BIIB019, Daclizumab, in Subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) Switching from Natalizumab (SUSTAIN)	No		45			25/01/2017	11/04/2017	11/04/2017		26/05/2017		03/07/2017	B - Suspended by sponsor	Sponsor
17/LO/1003	206965	Perforated Punctal Plug as an alternative to the three snip punctoplasty for the treatment of acquired lacrimal punctum stenosis	Yes	04/09/2017	0	24	24	22/03/2017	11/08/2017	01/08/2017	11/08/2017	11/08/2017		23/08/2017		
17/LO/1036	220972	Feasibility study for the use of intraoperative single dose radiotherapy for locally advanced and recurrent pelvic cancer	No		12			20/04/2017	05/10/2017	06/09/2017		17/10/2017		17/10/2017	I - Rare diseases	Neither

16/WM/0514	213012	The B-ADENOMA Study: Bowel Scope - Accuracy of Detection using ENdocuff Optimisation of Mucosal Abnormalities	No					30/03/2017	06/04/2017	06/04/2017	30/03/2017		Sponsor declined site con		J - Other	Sponsor
17/LO/0095	216048	A tailored, cognitive behavioural approach intervention for mild to moderate anxiety and/or depression in people with chronic obstructive pulmonary disease (COPD): A randomised controlled trial.	No		108				10/04/2017	08/03/2017		27/07/2017			D - Sponsor Delays	Sponsor
															H - Contracting delays	
16/NW/0877	216860	A Safety and Tolerability Study of LY3303560 in Alzheimer's Disease	Yes	06/10/2017	6	66	72	19/04/2017	26/07/2017	05/04/2017	19/04/2017	01/08/2017		01/09/2017	D - Sponsor Delays	Sponsor
16/SS/0137	199347	Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis 2	No		129			24/04/2017	07/11/2017	11/01/2017	24/04/2017	16/03/2018			D - Sponsor Delays	Sponsor
17/WM/0425	232819	A phase III trial evaluating the efficacy and safety of the SQ house dust mite (HDM) sublingual immunotherapy (SLIT)-tablet in children and adolescents with HDM allergic asthma	No		55			27/04/2017	24/11/2017	15/01/2018	18/01/2018	18/01/2018		08/03/2018	A - Permissions delayed/denied	Neither
17/SC/0122	224090	AR101 Trial in Europe Measuring Oral Immunotherapy Success in Peanut Allergic Children	Yes	18/07/2017	63	6	69	07/02/2017	10/05/2017	18/04/2017	12/07/2017	12/07/2017		14/07/2017	H - Contracting delays	
16/SC/0338	191612	Prospective Interruption of Therapy towards a Cure for HIV (PITCH) Pilot Study	No		196			09/05/2017	09/08/2017	22/11/2016	17/10/2017	21/02/2018			H - Contracting delays	Sponsor
16/YH/0157	204585	PLATO - PersonaLising Anal cancer radioTherapy dOse - Incorporating Anal Cancer Trials (ACT) ACT3, ACT4 and ACT5	No		128			26/08/2016	06/09/2017	20/07/2016		12/01/2018		18/01/2018	D - Sponsor Delays	Sponsor
															F - No patients seen	
17/LO/1129	226325	An adaptive orthosis for hand osteoarthritis; feasibility and prototype	Yes	04/10/2017	7	20	27	08/09/2017	07/09/2017	07/09/2017	08/09/2017	14/09/2017		14/09/2017		
17/NE/0165	217768	AN OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH EARLY STAGE RELAPSING REMITTING MULTIPLE SCLEROSIS	Yes	21/11/2017	133	21	154	22/05/2017	20/06/2017	07/09/2017	22/05/2017	31/10/2017		14/11/2017	D - Sponsor Delays	Sponsor
															H - Contracting delays	
16/SW/0120	201715	Study of the optimum duration of acoustic pulse thrombolysis procedure in the treatment of acute submassive pulmonary embolism	No		228			31/05/2017	03/08/2017	04/10/2016	19/03/2018	19/03/2018			D - Sponsor Delays	Sponsor
															H - Contracting delays	
17/LO/0525	221541	A prospective, double-masked, randomized, multicenter, active-controlled, parallel-group, 6-month study assessing the safety and ocular hypotensive efficacy of PG324 Ophthalmic Solution compared to GANFORTÂ® (bimatoprost 0.03%/timolol 0.5%) Ophthalmic Solution in subjects with elevated intraocular pressure (MERCURY 3).	No		37			05/12/2016	25/10/2017	30/06/2017	30/11/2017	01/12/2017		16/01/2018	J - Other	Sponsor
17/LO/0848	222163	A Phase 3, Randomized, Double-Blind, Placebo-Controlled StudyEvaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis	No		42				11/10/2017	02/08/2017		22/11/2017		24/11/2017	D - Sponsor Delays	Sponsor
															F - No patients seen	
															H - Contracting delays	
17/LO/0849	222165	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)	Yes	04/12/2017	43	11	54		11/10/2017	02/08/2017		23/11/2017		24/11/2017		
17/EM/0154	222912	A Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety and Tolerability of 28-Day Oral Treatment with PXT002331 (foliglurax) in Reducing Motor Complications of Levodopa Therapy in Subjects with Parkinson's Disease Experiencing End-of-dose Wearing Off and Levodopa- Induced Dyskinesia (AMBLED)	Yes	02/02/2018	4	115	119	08/06/2017	06/10/2017	27/06/2017	08/06/2017	10/10/2017		17/01/2018	D - Sponsor Delays	Sponsor
17/LO/0719	226571	Assessment of viral shedding in children previously in receipt of multiple doses of live attenuated influenza vaccine (LAIV) compared to influenza vaccine-naïve controls	Yes	16/10/2017	31	7	38	20/06/2017	08/09/2017	20/06/2017	04/10/2017	09/10/2017		16/10/2017		

17/EM/0236	221138	Dose finding phase IIb study of Bavisant to evaluate its safety and effiCacy in treAtment of exceSsive daytime sleePiness (EDS) in PARkinson's Disease (PD).	No		0			19/06/2017	18/12/2017	08/08/2017	19/06/2017	18/12/2017			H - Contracting delays	Sponsor
18/LO/0091	140718	Side-Stream Dark Field video analysis of cerebral microcirculation in patients with traumatic brain injury or a brain tumour: the effects of blood pressure and intracranial pressure	No		32			12/12/2017	12/02/2018	12/02/2018		16/03/2018				
17/YH/0296	222979	Optimising the identification of acute deterioration and sepsis through wearable sensors and digital alerting.	No					04/08/2017	16/10/2017	27/09/2017					D - Sponsor Delays	Sponsor
17/LO/1390	229748	Distribution of targeted educational materials to families after they attend emergency or urgent care with a child under 5 years old in non-urgent situation, in order to reduce future repeat non-urgent attendances	Yes	13/10/2017	35	36	71	12/07/2017	03/08/2017	05/09/2017	07/09/2017	07/09/2017		07/09/2017	J - Other	Neither
17/LO/1091	229631	A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of the Combination Regimen of MK-3682B (Grazoprevir/Ruzasvir/Uprifosbuvir) in Participants with Chronic Hepatitis C Virus Genotype 3 Infection	No					03/07/2017	24/08/2017	24/08/2017			Sponsor declined site con		B - Suspended by sponsor	Sponsor
17/NW/0352	226135	Resuscitative Endovascular Balloon Occlusion of the Aorta for Trauma	No		159			03/07/2017	05/10/2017	10/08/2017		13/03/2018		13/03/2018	D - Sponsor Delays	Sponsor
															H - Contracting delays	
17/SC/0164	210735	A multi-centre, randomised, controlled trial evaluating the effects of early high-dose cryoprecipitate in adult patients with major trauma haemorrhage requiring major haemorrhage protocol (MHP) activation	Yes	06/09/2017	84	6	90	08/06/2017	08/06/2017	26/05/2017	23/08/2017	31/08/2017		31/08/2017	E - Staff availability issues	NHS Provid
17/EM/0301	209448	Sedation and Weaning in Children	Yes	05/02/2018	16	46	62	13/07/2017	05/12/2017	29/09/2017	20/12/2017	21/12/2017				
17/EE/0387	231908	Maraviroc Add-On Therapy for Steatohepatitis in HIV	No						08/03/2018	08/03/2018						
17/LO/1568	232931	Pharmacokinetics of Intramuscular Adrenaline in Food-Allergic Teenagers - does dose matter? The PIMAT study	Yes	16/12/2017	26	38	64	30/08/2017	13/10/2017	30/10/2017	08/11/2017	08/11/2017			A - Permissions delayed/denied	Neither
17/LO/1522	216857	A randomized, double-blind, placebo-controlled, two-cohort parallel group study to evaluate the efficacy of CAD106 and CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's disease	No					31/07/2017	26/03/2018	28/11/2017	31/07/2017					
17/LO/1245	208149	A randomised controlled trial to assess the clinical and cost effectiveness of topical lactic acid gel for treating second and subsequent episodes of bacterial vaginosis	Yes	08/03/2018	25	31	56	11/09/2017	11/01/2018	10/11/2017	11/09/2017	05/02/2018				
17/EE/0026	220207	A Prospective, Randomized, Controlled, Multi-Center Clinical Study of theACRYSOF IQ Extended Depth of Focus (EDF) IOL	Yes	05/01/2018	69	85	154	15/02/2017	04/08/2017	19/06/2017	21/09/2017	12/10/2017		16/10/2017	F - No patients seen	Sponsor
															H - Contracting delays	
17/EM/0361	234065	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies (AFFINITY)	No		14			20/09/2017	28/02/2018	11/01/2018	20/09/2017	14/03/2018				
16/LO/0831	196728	Efficacy, safety and impact on antimicrobial resistance of duration and dose of amoxicillin treatment with Community-Acquired Pneumonia (CAP): a randomised controlled trial	No		133			20/06/2017	26/10/2017	11/11/2016	08/03/2018	08/03/2018			D - Sponsor Delays	Sponsor
17/LO/0380	218003	PET-LONGITUDINAL SUBSTUDY ASSOCIATED WITH: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER'S DISEASE	No		0			25/01/2018	25/01/2018	18/05/2017	25/01/2018	25/01/2018				
17/SC/0582	234404	A multicentre, open-label, long-term safety study of AR101 characterised oral desensitisation immunotherapy in subjects who participated in a prior AR101 study	No					24/10/2017	24/01/2018	18/01/2018					D - Sponsor Delays	Sponsor
															H - Contracting delays	

16/LO/0680	186642	Strategy for maintenance of HIV suppression with elvitegravir+darunavir/ritonavir in children (PENTA 17). A two-arm, phase 2/3 multicentre, open-label, randomised study evaluating safety and anti-viral effect of current anti-retroviral therapy compared to elvitegravir (EVG) administered with darunavir/ritonavir (DRV/r) in HIV-1 infected, virologically suppressed paediatric participants	No		39			08/11/2017	29/01/2018	28/07/2016	09/03/2018	09/03/2018		04/04/2018		
17/LO/1478	226023	A phase IIIb, open-label, multicentre, international randomised controlled trial of simplified treatment monitoring for 8 weeks glecaprevir (300mg)/pibrentasvir (120mg) in chronic HCV treatment naïve patients without cirrhosis	Yes	08/03/2018	64	14	78	22/09/2017	20/12/2017	23/11/2017	22/09/2017	22/02/2018			D - Sponsor Delays	Sponsor
															H - Contracting delays	
17/EE/0474	229785	The open-label, randomised, multi-centre, parallel group, two-arm study to assess the safety, overall tolerability, and antiviral activity of Brincidofovir versus standard of care for treatment of adenovirus infections in high-risk paediatric allogeneic haematopoietic cell transplant recipients	No		23			14/07/2017	10/01/2018	05/01/2018	02/02/2018	02/02/2018		20/02/2018	G - No patients consented	Neither
18/LO/0314	237195	Smart Catheter: A novel biosensor for early diagnosis of catheter associated urinary tract infection	No		14				28/03/2018	06/04/2018		11/04/2018				
17/SC0639	236312	A Phase 3 Open-Label, single-Arm Study to Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII at a dose of 4E13 vg/kg in Haemophila A Patients with Residual FVIII Levels 1 IU/dL Receiving Prophylactic FVIII Infusions	No		80			09/01/2018	15/01/2018	26/02/2018	22/03/2018	05/04/2018			H - Contracting delays	Sponsor
17/EM/0412	234907	An adaptive seamless randomized, double-blind, placebocontrolled, dose ranging study to investigate the efficacy and safety of LNP023 in primary IgA nephropathy patients	No					15/01/2018	13/02/2018	04/12/2017					D - Sponsor Delays	Sponsor
18/LO/0170	236855	A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in combination with Standard of Care as Adjuvant Therapy for Stage III-IVB Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)	No					29/01/2018	26/03/2018							
18/NW/0031	230387	A multi-centre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (NEC))	No					12/02/2018	12/02/2018	08/02/2018						
18/SC/0057	230986	A prospective cross-sectional study analysing the utility of novel tablet-based audiometry and an interactive web-based hearing app as screening tools for drug-induced ototoxicity in adults with cystic fibrosis.	No						19/03/2018							
18/LO/0393	240955	A Phase I, Open-Label, Ascending Dose Study to Assess the Safety and Tolerability of AAV2/6 Factor IX Gene Therapy via Zinc Finger Nuclease (ZFN) mediated targeted integration of SB-FIX in Subjects with Severe Haemophilia B	No						19/03/2018							
16/LO/2150	201093	Randomised Phase II Trial of olaparib, chemotherapy or olaparib and cediranib in patients with BRCA mutated platinum–resistant ovarian cancer	No					20/03/2018	20/03/2018	26/01/2017						